Page last updated: 2024-12-11

gambierol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

gambierol: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID6442244
CHEMBL ID266438
MeSH IDM0400087

Synonyms (8)

Synonym
CHEMBL266438
(-)-gambierol
unii-844q8wc5f6
844q8wc5f6 ,
gambierol
146763-62-4
(1s,3r,5s,7r,10s,11r,13s,15r,17s,20r,22s,24r,26s,27s,29s,31r,33s,35r)-11-[(1z,3z)-hepta-1,3,6-trienyl]-29-(3-hydroxypropyl)-3,5,10,24,26-pentamethyl-2,6,12,16,21,25,30,34-octaoxaoctacyclo[18.16.0.03,17.05,15.07,13.022,35.024,33.026,31]hexatriacont-8-ene-1
DTXSID30880110

Research Excerpts

Overview

Gambierol is a marine polycyclic ether toxin produced by the marine dinoflagellate Gambierdiscus toxicus and is a member of the ciguatoxin toxin family. It primarily targets voltage-gated potassium channels (K(v) channels) in excitable membranes.

ExcerptReferenceRelevance
"Gambierol is a polycyclic ether toxin, isolated as a toxic constituent from the marine dinoflagellate Gambierdiscus toxicus. "( Synthesis and biological evaluation of gambierol analogues.
Fuwa, H; Kainuma, N; Sasaki, M; Satake, M, 2003
)
2.03
"Gambierol is a marine polycyclic ether toxin produced by the marine dinoflagellate Gambierdiscus toxicus and is a member of the ciguatoxin toxin family. "( Gambierol inhibition of voltage-gated potassium channels augments spontaneous Ca2+ oscillations in cerebrocortical neurons.
Busse, E; Cao, Z; Cui, Y; Mehrotra, S; Murray, TF; Rainier, JD, 2014
)
3.29
"Gambierol is a marine polycyclic ether toxin, produced along with ciguatoxin congeners by the dinoflagellate Gambierdiscus toxicus. "( Potassium currents inhibition by gambierol analogs prevents human T lymphocyte activation.
Botana, LM; Fuwa, H; Martín, V; Rubiolo, JA; Sasaki, M; Vale, C, 2015
)
2.14
"Gambierol is a marine polycyclic ether toxin belonging to the group of ciguatera toxins. "( A polyether biotoxin binding site on the lipid-exposed face of the pore domain of Kv channels revealed by the marine toxin gambierol.
Cuypers, E; Johnson, HW; Kopljar, I; Labro, AJ; Rainier, JD; Snyders, DJ; Tytgat, J, 2009
)
2
"Gambierol is a marine polyether ladder toxin derived from the dinoflagellate Gambierdiscus toxicus. "( Calcium oscillations induced by gambierol in cerebellar granule cells.
Alonso, E; Botana, LM; Fuwa, H; Konno, Y; Perez, S; Sasaki, M; Vale, C; Vieytes, MR, 2010
)
2.09
"Gambierol is a complex marine toxin first isolated with ciguatoxins from cell cultures of the toxic dinoflagellate Gambierdiscus toxicus. "( The marine polyether gambierol enhances muscle contraction and blocks a transient K(+) current in skeletal muscle cells.
Benoit, E; Botana, LM; Fuwa, H; Girard, E; Louzao, MC; Molgó, J; Ouanounou, G; Sasaki, M; Schlumberger, S, 2010
)
2.12
"Gambierol is a potent neurotoxin that belongs to the family of marine polycyclic ether natural products and primarily targets voltage-gated potassium channels (K(v) channels) in excitable membranes. "( Design and synthesis of skeletal analogues of gambierol: attenuation of amyloid-β and tau pathology with voltage-gated potassium channel and N-methyl-D-aspartate receptor implications.
Alonso, E; Botana, LM; Fuwa, H; Giménez-Llort, L; Goto, T; Konno, Y; LaFerla, FM; Sasaki, M; Suga, Y; Vale, C; Vieytes, MR, 2012
)
2.08
"Gambierol is a marine polycyclic ether toxin, first isolated along with ciguatoxin congeners from the dinoflagellate Gambierdiscus toxicus."( Effect of gambierol and its tetracyclic and heptacyclic analogues in cultured cerebellar neurons: a structure-activity relationships study.
Alonso, E; Botana, LM; Fuwa, H; Goto, T; Konno, Y; Pérez, S; Sasaki, M; Suga, Y; Vale, C; Vieytes, MR, 2012
)
1.5
"Gambierol is a polycyclic ether toxin, which has been isolated from the marine dinoflagellate Gambierdiscus toxicus. "( Diverted total synthesis and biological evaluation of gambierol analogues: elucidation of crucial structural elements for potent toxicity.
Fuwa, H; Kainuma, N; Sasaki, M; Satake, M; Tachibana, K; Tsukano, C, 2004
)
2.01
"Gambierol is a polycyclic ether toxin with the same biogenetic origin as ciguatoxins. "( The sodium channel of human excitable cells is a target for gambierol.
Botana, LM; Cagide, E; Fuwa, H; Louzao, MC; Sasaki, M; Vieytes, MR; Yasumoto, T, 2006
)
2.02

Effects

Gambierol has been associated with neurological symptoms in humans. Its mechanism of action has not been fully characterized.

ExcerptReferenceRelevance
"Gambierol has been demonstrated to be either a low-efficacy partial agonist/antagonist of voltage-gated sodium channels or a potent blocker of voltage-gated potassium channels (Kvs)."( Gambierol inhibition of voltage-gated potassium channels augments spontaneous Ca2+ oscillations in cerebrocortical neurons.
Busse, E; Cao, Z; Cui, Y; Mehrotra, S; Murray, TF; Rainier, JD, 2014
)
2.57
"Gambierol has been associated with neurological symptoms in humans even though its mechanism of action has not been fully characterized."( The sodium channel of human excitable cells is a target for gambierol.
Botana, LM; Cagide, E; Fuwa, H; Louzao, MC; Sasaki, M; Vieytes, MR; Yasumoto, T, 2006
)
1.3

Toxicity

ExcerptReferenceRelevance
" In many cases, the lack of toxic material turns out to be an obstacle to make the toxicological investigations needed."( Comparative cytotoxicity of gambierol versus other marine neurotoxins.
Ares, IR; Botana, LM; Cagide, E; Espiña, B; Fuwa, H; Konno, Y; Louzao, MC; Paquette, LA; Sasaki, M; Tsukano, C; Vieytes, MR; Yasumoto, T; Yotsu-Yamashita, M, 2011
)
0.66
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID212037Minimal lethal dose of compound expressed as toxicity against male mice (ddY strain) after intraperitoneal administration2003Bioorganic & medicinal chemistry letters, Aug-04, Volume: 13, Issue:15
Synthesis and biological evaluation of gambierol analogues.
AID1177025Induction of leak current in wild-type CHO cells by electrophysiology method2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Evaluation of gambierol and its analogs for their inhibition of human Kv1.2 and cytotoxicity.
AID1177027Cytotoxicity against CHO cells transfected with human Kv 1.2 assessed as growth inhibition after 72 hrs by WST-8 assay2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Evaluation of gambierol and its analogs for their inhibition of human Kv1.2 and cytotoxicity.
AID1177024Inhibition of human Kv 1.2 stably expressed in CHO cells by whole cell patch clamp method2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Evaluation of gambierol and its analogs for their inhibition of human Kv1.2 and cytotoxicity.
AID1177026Cytotoxicity against wild-type CHO cells assessed as growth inhibition after 72 hrs by WST-8 assay2015Bioorganic & medicinal chemistry letters, Feb-01, Volume: 25, Issue:3
Evaluation of gambierol and its analogs for their inhibition of human Kv1.2 and cytotoxicity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (44)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's29 (65.91)29.6817
2010's14 (31.82)24.3611
2020's1 (2.27)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.84 (24.57)
Research Supply Index3.81 (2.92)
Research Growth Index4.35 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews4 (9.09%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other40 (90.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]